<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562923</url>
  </required_header>
  <id_info>
    <org_study_id>AI-FSX-001</org_study_id>
    <nct_id>NCT03562923</nct_id>
  </id_info>
  <brief_title>A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50</brief_title>
  <official_title>A Randomized Single Blind Placebo-Controlled Multi-Center Study Comparing Combination Therapy With Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder to Combination Therapy With ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder) in Treatment of Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Ireland Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amneal Ireland Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety profiles of Fluticasone Propionate 100 mcg and Salmeterol&#xD;
      50 mcg Inhalation Powder (test product) and ADVAIR DISKUS (fluticasone propionate 100 mcg and&#xD;
      salmeterol 50 mcg inhalation powder) (reference product) and to show that the efficacy of the&#xD;
      2 active products is superior to that of placebo in the treatment of subjects with asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline-adjusted area under the serial FEV1-time curve</measure>
    <time_frame>0-12 hours after dosing on day 1</time_frame>
    <description>Baseline-adjusted area under the serial FEV1-time curve calculated from time zero to 12 hours (AUC0-12h) on the first day of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted, pre-dose FEV1</measure>
    <time_frame>4-weeks</time_frame>
    <description>Baseline-adjusted, pre-dose FEV1 on the last day of a 4-week treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1204</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Product, 100/50 mcg, 2 x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Product, 100/50 mcg, 2 x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Product 2 x daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Product</intervention_name>
    <description>Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder</description>
    <arm_group_label>Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Product</intervention_name>
    <description>ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)</description>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>ADVAIR DISKUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Product</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects (≥ 12 years of age) of non-child bearing potential or of child&#xD;
             bearing potential committing to consistent and correct use of an acceptable method of&#xD;
             birth control.&#xD;
&#xD;
          -  Diagnosed with asthma as defined by the National Asthma Education and Prevention&#xD;
             Program (NAEPP) at least 12 weeks prior to screening.&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 of ≥40% and ≤85% of the predicted value during the screening&#xD;
             visit and on the first day of treatment.&#xD;
&#xD;
          -  Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe&#xD;
             tobacco) within the past year, and had ≤ 10 pack-years of historical use.&#xD;
&#xD;
          -  ≥15% reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation&#xD;
             (pMDI).&#xD;
&#xD;
          -  Able to discontinue their asthma medications (inhaled corticosteroids and long-acting&#xD;
             β agonists) during the run-in period and for remainder of the study.&#xD;
&#xD;
          -  Able to replace current short-acting β agonists (SABAs) with salbutamol/albuterol&#xD;
             inhaler for use as needed for the duration of the study (subjects should be able to&#xD;
             withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on&#xD;
             study visits).&#xD;
&#xD;
          -  Able to continue the following medications without a significant adjustment of dosage,&#xD;
             formulation, dosing interval for the duration of the study, and judged able by the&#xD;
             investigator to withhold them for the specified minimum time intervals prior to each&#xD;
             clinic visit:&#xD;
&#xD;
               -  short-acting forms of theophylline 12 hours&#xD;
&#xD;
               -  twice-a-day controlled-release forms of theophylline 24 hours&#xD;
&#xD;
               -  once-a-day controlled-release forms of theophylline 36 hours&#xD;
&#xD;
               -  Able to discontinue the following medications for the specified minimum time&#xD;
                  intervals prior to the run-in period and for the remainder of the study:&#xD;
&#xD;
               -  oral corticosteroids 1 month&#xD;
&#xD;
               -  parenteral corticosteroids 1 month&#xD;
&#xD;
               -  oral short-acting β-agonists 12 hours&#xD;
&#xD;
          -  Willingness to give their (and in the case of a minor their parent/guardian was able&#xD;
             to give) written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life-threatening asthma, defined as a history of asthma episode(s) requiring&#xD;
             intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic&#xD;
             seizures, asthma related syncopal episode(s), or hospitalizations within the past year&#xD;
             or during the run-in period.&#xD;
&#xD;
          -  Evidence or history of clinically significant disease or abnormality including&#xD;
             congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery&#xD;
             disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or&#xD;
             current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal,&#xD;
             or other diseases that in the opinion of the investigator, would put the patient at&#xD;
             risk through study participation, or would affect the study analyses if the disease&#xD;
             exacerbated during the study.&#xD;
&#xD;
          -  Hypersensitivity to any sympathomimetic drug (e.g., salmeterol or albuterol) or any&#xD;
             inhaled, intranasal, or systemic corticosteroid therapy.&#xD;
&#xD;
          -  Medication(s) with the potential to affect the course of asthma or to interact with&#xD;
             sympathomimetic amines, e.g.:&#xD;
&#xD;
               -  β-blockers&#xD;
&#xD;
               -  oral decongestants&#xD;
&#xD;
               -  benzodiazepines&#xD;
&#xD;
               -  digitalis&#xD;
&#xD;
               -  phenothiazines&#xD;
&#xD;
               -  polycyclic antidepressants&#xD;
&#xD;
               -  Monoamine oxidase inhibitors&#xD;
&#xD;
          -  Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear&#xD;
             infection within 4 weeks prior to the screening visit or during the run-in period.&#xD;
&#xD;
          -  Factors (e.g., infirmity, disability or geographic location) that the investigator&#xD;
             felt would likely limit the patient's compliance with the study protocol or scheduled&#xD;
             clinic visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irshad Haque</last_name>
    <role>Study Director</role>
    <affiliation>Amneal Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irshad Haque</last_name>
    <phone>631-952-0214</phone>
    <email>ihaque@amneal.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

